Diagnosis of mitochondrial dysfunction in HIV-infected patients under highly active antiretroviral therapy: Possibilities beyond the standard procedures

Antiviral Therapy

Volumn 10, Issue SUPPL. 2, 2005, Pages

  Casademont, Jordi ^a   Sanjurjo, Eduard ^a   Garrabou, Gloria ^a   Miró, Òscar ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BREATH ANALYSIS; CARDIOPULMONARY HEMODYNAMICS; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DIFFUSION WEIGHTED IMAGING; EXERCISE TEST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MITOCHONDRIAL TOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BREATH TESTS; EXERCISE TEST; HIV INFECTIONS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MITOCHONDRIA; SPECTROSCOPY, NEAR-INFRARED;

EID: 24044472462     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Wallace CD. Diseases of mitochondrial DNA. Annual Review of Biochemistry 1992; 61:1175-1212.
2. Cardellach F, Casademont J & Urbano-Marquez A. Mitocondriopatias secundarias. Revista de Neurologia 1998; 26(Suppl 1):S81-S86.
3. Schapira AH. Primary and secondary defects of the mitochondrial respiratory chain. Journal of Inherited Metabolic Disease 2002; 25:207-214.
4. Casademont J, Barrientos A, Grau JM, Pedrol E, Estivill X, Urbano-Marquez A & Nunes V. The effect of zidovudine on skeletal muscle mtDNA in HIV-1 infected patients with mild or no muscle dysfunction. Brain 1996; 119:1357-1364.
5. Zaera MG, Miro O, Pedrol E, Soler A, Picon M, Cardellach F, Casademont J & Nunes V. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS 2001; 15:1643-1651.
6. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O'Shaughnessy MV & Montaner JS. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. New England Journal of Medicine 2002; 346:811-820.
7. Casademont J, Miró O & Cardellach F. Mitochondrial DNA and nucleoside toxicity. New England Journal of Medicine 2002; 347:217.
8. Walker UA, Bickel M, Lutke Volksbeck SI, Ketelsen UP, Schofer H, Setzer B, Venhoff N, Rickerts V & Staszewski S. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 2002; 29:117-121.
9. Miro O, Lopez S, Pedrol E, Rodriguez-Santiago B, Martinez E, Soler A, Milinkovic A, Casademont J, Nunes V, Gatell JM & Cardellach F. Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy. Antiviral Therapy 2003; 8:333-338.
10. Miro O, Lopez S, Martinez E, Rodriguez-Santiago B, Blanco JL, Milinkovic A, Miro JM, Nunes V, Casademont J, Gatell JM & Cardellach F. Short communication: reversible mitochondrial respiratory chain impairment during symptomatic hyperlactatemia associated with anti-retroviral therapy. AIDS Research & Human Retroviruses 2003; 19:1027-1032.
11. Cossarizza A & Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 2004; 18:137-151.
12. Lopez S, Miro O, Martinez E, Pedrol E, Rodriguez-Santiago B, Milinkovic A, Soler A, Garcia-Viejo MA, Nunes V, Casademont J, Gatell JM & Cardellach F. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antiviral Therapy 2004; 9:47-55.
13. de Martino M, Zammarchi E, Filippi L, Donati MA, Mannelli F, Galli L & Vierucci A. Redox potential status in children with perinatal HIV-1 infection treated with zidovudine. AIDS 1995; 9:1381-1383.
14. 13C-methionine breath test. Scandinavian Journal of Gastroenterology 2000; 35:650-653.
15. 13C-breath tests in the study of mitochondrial liver function. European Review for Medical & Pharmacological Sciences 2004; 8:23-31.
16. 13C-methionine breath test detects liver mitochondrial impairment in HIV-infected patients with anti-retroviral drug-related hyperlactatemia. Journal of Acquired Immune Deficiency Syndromes 2004; 35:429-432.
17. 13C-methionine breath test. Antiviral Therapy 2004; 9:L19.
18. Versalovic J. Helicobacter pylori. Pathology and diagnostic strategies. American Journal of Clinical Pathology 2003; 119:403-412.
19. ATS/ACCP. Statement on cardiopulmonary exercise testing. American Journal of Respiratory & Critical Care Medicine 2003; 167:211-277.
20. Mayers JN. The physiology behind exercise testing. Primary Care 2001; 28:5-28.
21. Dandurand RJ, Matthews PM, Arnold DL & Eidelman DH. Mitochondrial disease. Pulmonary function, exercise performance, and blood lactate levels. Chest 1995; 108:182-189.
22. Taivassalo T, Jensen TD, Kennaway N, DiMauro S, Vissing J & Haller RG. The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients. Brain 2003; 126:413-423.
23. Tesiorowski AM, Harris M, Chan KJ, Thompson CR & Montaner JS. Anaerobic threshold and random venous lactate levels among HIV-positive patients on antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2002; 31:250-251.
24. Chapplain JM, Beillot J, Begue JM, Souala F, Bouvier C, Arvieux C, Tattevin P, Dupont M, Chapon F, Duvauferrier R, Hespel JP, Rochcongar P & Michelet C. Mitochondrial abnormalities in HIV-infected lipoatrophic patients treated with antiretroviral agents. Journal of Acquired Immune Deficiency Syndromes 2004; 37:1477-1488.
25. Roge BT, Calbet JA, Moller K, Ullum H, Hendel HW, Gerstoft J & Pedersen BK. Skeletal muscle mitochondrial function and exercise capacity in HIV-infected patients with lipodystrophy and elevated p-lactate levels. AIDS 2002; 16:973-982.
26. Johnson JE, Anders GT, Blanton HM, Hawkes CE, Bush BA, McAllister CK & Matthews JI. Exercise dysfunction in patients seropositive for the human immunodeficiency virus. American Review of Respiratory Disease 1990; 141:618-622.
27. Stringer WW. Mechanisms of exercise limitation in HIV+ individuals. Medicine & Science in Sports & Exercise 2000; 32(7 Suppl):S412-S421.
28. Munsat TL. A standardized forearm ischemic exercise test. Neurology 1970; 20:1171-1178.
29. Sanjurjo E, Laguno M, Bedini JL, Miro O & Grau JM. Forearm ischemic exercise test. Standardization and diagnostic value in the identification of McArdle disease. Medicina Clinica 2004; 122:761-766.
30. Clark JB, Bates TE, Boakye P, Kuimov A & Land JM. Investigation mitochondrial defects in brain and skeletal muscle. In A Practical Approach to the Investigation of Metabolic Disease, 1996, pp. 151-174. Edited by AJ Turner & HS Batchelard. Oxford: IRL Press, Oxford University Press.
31. Dysgaard Jeppesen T, Olsen D & Vissing J. Cycle ergometry is not a sensitive diagnostic test for mitochondrial myopathy. Journal of Neurology 2003; 250:293-299.
32. Jensen TD, Kazemi-Esfarjani P, Skomorowska E & Vissing J. A forearm exercise screening test for mitochondrial myopathy. Neurology 2002; 58:1533-1538.
33. Garrabou G, López S, Sanjurjo E, Infante A, Riba J, Casademont J, Cardellach F & Miro O. Mitochondrial dysfunction of HAART-related hyperlactataemia is demonstrable by non-invasive studies. Antiviral Therapy 2004; 9:L24.
34. Abe K, Matsuo Y, Kadekawa J, Inoue S & Yanagihara T. Measurement of tissue oxygen consumption in patients with mitochondrial myopathy by noninvasive tissue oximetry. Neurology 1997; 49:837-841.
35. Beekvelt M, Engelen B, Wevers R & Colier W. Quantitative near-infrared spectroscopy discriminates between mitochondrial myopathies and normal muscle. Annals of Neurology 1999; 46:667-670.
36. Parry A & Matthews PM. Roles for imaging in understanding the patophysiology, clinical evaluation, and management of patients with mitochondrial disease. Journal of Neuroimaging 2003; 13:293-302.
37. 31P MRS study. NMR in Biomedicine 1996; 9:165-172.
38. Matthews PM, Allaire C, Shoubridge EA, Karpati G, Carpenter S & Arnold DL. In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondrial disease. Neurology 1991; 41:114-120.
39. Mattei JP, Bendahan D & Cozzone P. P-31 magnetic resonance spectroscopy. A tool for diagnostic purposes and pathophysiological insights in muscle diseases. Reumatismo 2004; 56:9-14.
40. Argov Z. Functional evaluation techniques in mitochondrial disorders. European Neurology 1998; 39:65-71.
41. Cea G, Bendahan D, Manners D, Hilton-Jones D, Lodi R, Styles P & Taylor DJ. Reduced oxidative phosphorylation and proton efflux suggest reduced capillary blood supply in skeletal muscle of patients with dermatomyositis and polymyositis: a quantitative 31P-magnetic resonance spectroscopy and MRI study. Brain 2002; 125:1635-1645.